TAIWAN-PLUS
30.8.2021 17:40:11 CEST | Business Wire | Press release
Taiwan Plus (Taiwan+), the first English-language international streaming platform of Taiwan, was unveiled by Vice President Lai Ching-te, Legislative Speaker You Si-kun, Culture Minister Lee Yung-te, Central News Agency (CNA) Chairman Liu Ka-shiang, Taiwan+ CEO Joanne Tsai, and H.E. Ambassador Jasmine E. Huggins of Embassy of Saint Christopher and Nevis at the National Taiwan Museum in Taipei on Aug. 30.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005461/en/
Targeting English-speaking audience, Taiwan+ consists of media professionals from the U.S., the U.K, Canada, France, and Australia, as well as local industry professionals, who work collaboratively to deliver the latest news about Taiwan, international affairs, and covers a wide range of topics. The platform also sources stories from Taiwan’s public and private media organizations.
Golden Melody-award winning singer Sanpuy Katatepan Mavaliyw opened the event with a music performance. Held with COVID-19 prevention measures in place, the event was joined by representatives including Izumi Hiroyasu from Japan, Jordan Reeves from Canada, Andrew Wylegala and Don Shapiro from the U.S., and Henry Chang and Giuseppe Izzo from Europe.
H.E. Ambassador Jasmine E. Huggins of Embassy of Saint Christopher and Nevis in Taiwan said the international video platform is expected to connect Taiwan with the world.
President Tsai Ing-wen expressed her pleasure to join the launch of Taiwan+ with a video message, saying “Taiwan+ is an exciting new initiative to tell Taiwan’s story. Generations of Taiwanese fought to transform this country into a vibrant democracy that protects freedom of speech and expression.”
Premier Su Tseng-chang wished the platform success. He stressed that Taiwan is a democratic and free country guided by the rule of law, and cares about universal values of human rights, freedom of speech and diversity, noting that this is why many countries are willing to make friends and do business with Taiwan.
Vice President Lai said, “I hope that the platform can be the starting point from which the world learns about what Taiwanese people think and want, what Taiwan is doing, and what we can contribute to the world.”
Legislative Speaker You noted that, with China’s intimidation and political oppression against Taiwan, the establishment of Taiwan+ allows Taiwan to tell its stories to the world through its voices.
Taiwan+, a project commissioned by the Ministry of Culture to the CNA, marks an important milestone in the country’s history of mass media, Minister Lee said. He expressed his gratitude to legislators and professionals for making this happen.
“I hope to make this platform a form of expansion, connection, and infinite possibilities, just like how Taiwan incorporates ethnic, cultural and linguistic diversity, and introduce Taiwan to the world through dynamic storytelling and news,” said Tsai, a senior media professional with over 25 years of experience in international media outlets, such as NBC/CNBC, National Geographic, and Fox International Channels.
The content of Taiwan+ can be played on the Taiwan Plus app or viewed on its website and social media platforms, such as Facebook, YouTube, Twitter, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005461/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
